Sign In
Buy HAE
$72.78
+0.250 (+0.345%)
At Close: Jun 23, 2026
BioCryst Pharmaceuticals: Management's Plans For Multibillion HAE Franchise Add Up
01:59pm, Monday, 15'th Jun 2026
BioCryst Pharmaceuticals, Inc. is upgraded to Buy, reflecting strong execution in HAE and a compelling pipeline with Orladeyo and navenibart. BCRX targets $1.8bn in revenues and $1bn in cash by 2033,
— Growing body of ORLADEYO ® clinical data and real-world evidence demonstrates consistent reductions in HAE attack burden and healthcare utilization across diverse patient populations
Pharvaris Announces Annual General Meeting of Shareholders
06:50am, Thursday, 11'th Jun 2026
ZUG, Switzerland, June 11, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet nee
Haemonetics Corporation (HAE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
07:18pm, Monday, 08'th Jun 2026
Haemonetics Corporation (HAE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Haemonetics Updates Financial Reporting Segments
06:30am, Friday, 05'th Jun 2026
BOSTON, June 5, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions designed to improve patient outcomes, today ann
Haemonetics to Present at Goldman Sachs 47th Annual Global Healthcare Conference
04:05pm, Tuesday, 02'nd Jun 2026
BOSTON, June 2, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, President and CEO, will participate in a fireside chat with investors at the Goldman Sachs 47th An
[url="]KalVista Pharmaceuticals[/url], Inc. (Nasdaq: KALV) today announced new data highlighting the burden of injectable on-demand treatment in children aged
RESEARCH TRIANGLE PARK, N.C., May 27, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present seven abstracts from its hereditary angioede
Investing in Haemonetics (HAE)? Don't Miss Assessing Its International Revenue Trends
10:15am, Friday, 22'nd May 2026
Examine the evolution of Haemonetics' (HAE) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects.
Is It Too Late to Buy Haemonetics Corp (HAE) After 4.0% Rally? GF Value Says Undervalued
08:21pm, Thursday, 21'st May 2026
On May 21, 2026, Haemonetics Corp (HAE) shares rose 4.0%, bringing the current price to $61.94. The stock has fluctuated significantly over the past year, with
Is the Options Market Predicting a Spike in Haemonetics Stock?
10:25am, Wednesday, 13'th May 2026
Investors need to pay close attention to GBTG stock based on the movements in the options market lately.
Haemonetics Corporation (HAE) Presents at Bank of America Global Healthcare Conference 2026 Transcript
01:20pm, Tuesday, 12'th May 2026
Haemonetics Corporation (HAE) Presents at Bank of America Global Healthcare Conference 2026 Transcript
HAE Stock Gains on Q4 Earnings & Revenue Beat, Gross Margin Cut
03:26pm, Monday, 11'th May 2026
Haemonetics beats Q4 EPS and revenue estimates, shares rise 1.4%, but gross margin falls 120 basis points as the company sets its FY27 growth outlook.
Haemonetics Q4 Earnings Call Highlights
03:05pm, Sunday, 10'th May 2026
Haemonetics NYSE: HAE reported fiscal fourth-quarter revenue of $346 million, up 5% on a reported basis and 9% organically excluding CSL, as strength in its Plasma and Blood Management Technologies bu
The London Company Small Cap Portfolio Q1 2026 Portfolio Review
05:11am, Friday, 08'th May 2026
Matson was the top performer as container shipping rates strengthened amid supply chain disruptions and management executed on operational efficiency initiatives. Revolve Group sold off as the online
